← Back to All US Stocks

FTII Stock Analysis 2026 - FutureTech II Acquisition Corp. AI Rating

FTII Biological Products, (No Diagnostic Substances) CIK: 0001889450
Recently Updated • Analysis: Mar 25, 2026 • SEC Data: 2025-06-30
STRONG SELL
95% Conf
Pending
Analysis scheduled

📊 FTII Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: $-1.2M
Current Ratio: 0.21x
Debt/Equity: N/A
EPS: $0.00
AI Rating: STRONG SELL with 95% confidence

Is FTII a Good Investment? Thesis Analysis

Claude

FutureTech II is a financially distressed acquisition company with negative stockholders' equity of -9.6M, indicating the company is technically insolvent. Severe liquidity constraints (current ratio of 0.21x) combined with negative operating cash flow of -1.2M and a cash position of only 160.7K creates an existential crisis. The company is burning cash rapidly with no revenue generation and mounting losses, making it unsuitable for equity investment.

Why Buy FTII? Key Strengths

Claude
  • + Company has not yet filed for bankruptcy or ceased operations
  • + Minimal insider selling pressure in last 90 days suggests no forced liquidations
  • + May have acquisition or reverse merger potential as a shell entity

FTII Investment Risks to Consider

Claude
  • ! Negative stockholders' equity of -9.6M indicates technical insolvency and shareholder claims are fully subordinated to creditors
  • ! Critical liquidity crisis: current ratio of 0.21x with only 160.7K cash against 10.4M liabilities threatens immediate solvency
  • ! Severe cash burn: negative operating cash flow of -1.2M annually with no revenue means remaining cash runway is less than 2 months
  • ! No revenue generation capability documented; operating losses of -320.3K indicate ongoing operations without income
  • ! Interest coverage ratio of -3.2x shows inability to service debt obligations
  • ! ROA of -3.5% confirms systematic destruction of asset value

Key Metrics to Watch

Claude
  • * Stockholders' equity trend - any further deterioration below -9.6M signals complete loss of equity cushion
  • * Cash balance - depletion below 100K would indicate imminent insolvency crisis
  • * Operating cash flow - must return to positive to assess viability; current -1.2M trajectory unsustainable
  • * Acquisition or merger announcement - structural solution required for survival
  • * Debt covenant compliance status and default risk timeline

FTII Financial Metrics

Revenue
N/A
Net Income
$-370.3K
EPS (Diluted)
$0.00
Free Cash Flow
$-1.2M
Total Assets
$10.6M
Cash Position
$160.7K

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

FTII Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA -3.5%
FCF Margin N/A

FTII vs Healthcare Sector

How FutureTech II Acquisition Corp. compares to Healthcare sector averages

Net Margin
FTII 0.0%
vs
Sector Avg 12.0%
FTII Sector
ROE
FTII 0.0%
vs
Sector Avg 15.0%
FTII Sector
Current Ratio
FTII 0.2x
vs
Sector Avg 2.0x
FTII Sector
Debt/Equity
FTII 0.0x
vs
Sector Avg 0.6x
FTII Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is FTII Overvalued or Undervalued?

Based on fundamental analysis, FutureTech II Acquisition Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

FTII Balance Sheet & Liquidity

Current Ratio
0.21x
Quick Ratio
0.21x
Debt/Equity
N/A
Debt/Assets
98.1%
Interest Coverage
-3.20x
Long-term Debt
N/A

FTII 5-Year Financial Trend & Growth Analysis

FTII 5-year financial data:
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: FutureTech II Acquisition Corp.'s revenue has remained relatively flat over the 5-year period, with a 0% decline.

FTII Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

FTII Capital Allocation

Operating Cash Flow
-$1.2M
Cash generated from operations
Stock Buybacks
$17.4M
Shares repurchased (TTM)
Dividends
None
No dividend program

FTII SEC 10-K & 10-Q Filing Analysis

Access official SEC EDGAR filings for FutureTech II Acquisition Corp. (CIK: 0001889450)

📋 Recent SEC Filings

Date Form Document Action
Mar 10, 2026 8-K form8-k.htm View →
Feb 19, 2026 8-K form8-k.htm View →
Jan 16, 2026 8-K form8-k.htm View →
Nov 12, 2025 8-K form8-k.htm View →
Aug 22, 2025 10-Q form10-q.htm View →

Frequently Asked Questions about FTII

What is the AI rating for FTII?

FutureTech II Acquisition Corp. (FTII) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.

What are FTII's key strengths?

Claude: Company has not yet filed for bankruptcy or ceased operations. Minimal insider selling pressure in last 90 days suggests no forced liquidations.

What are the risks of investing in FTII?

Claude: Negative stockholders' equity of -9.6M indicates technical insolvency and shareholder claims are fully subordinated to creditors. Critical liquidity crisis: current ratio of 0.21x with only 160.7K cash against 10.4M liabilities threatens immediate solvency.

What is FTII's revenue and growth?

FutureTech II Acquisition Corp. reported revenue of N/A.

Does FTII pay dividends?

FutureTech II Acquisition Corp. does not currently pay dividends.

Where can I find FTII SEC filings?

Official SEC filings for FutureTech II Acquisition Corp. (CIK: 0001889450) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is FTII's EPS?

FutureTech II Acquisition Corp. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is FTII a good stock to buy right now?

Based on our AI fundamental analysis in March 2026, FutureTech II Acquisition Corp. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is FTII stock overvalued or undervalued?

Valuation metrics for FTII: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy FTII stock in 2026?

Our dual AI analysis gives FutureTech II Acquisition Corp. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is FTII's free cash flow?

FutureTech II Acquisition Corp.'s operating cash flow is $-1.2M, with capital expenditures of N/A.

How does FTII compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.21 (avg: 2).

Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 25, 2026 | Data as of: 2025-06-30 | Powered by Claude AI